- info@chironthx.com
- +1 (647) 268-7151
- 6936 Sparkling Lake Way, Ottawa, ON CANADA K4P 1R7
To deliver safe, scalable, and effective adult stem cell products for cosmetic and therapeutic applications.
To deliver safe, scalable, and effective adult stem cell products for cosmetic and therapeutic applications.
Our IP-licensed method generates large quantities of tissue-specific adult stem cells from somatic cells without transgenes or viruses.
Our technology allows for the generation of therapeutic cells from easily accessible tissues like skin, reducing patient discomfort.
Current stem cell methods risk patient safety, creating an urgent need for safer, non-transgenic and virus-free approach to produce scalable adult stem cells for therapy.
By eliminating genetic manipulation, our approach significantly reduces the risk of tumorigenesis and genetic instabilities.
The Suspension-Induced Stem Cell Transition (SIST) technology is our proprietary method for generating tissue-specific adult stem cells without genetic modification or viral vectors.
Our closed-loop process takes cells from collection to treatment with our revolutionary SIST reprogramming method.
At Chiron Therapeutics, we are reimagining what is possible in cell therapy. Inspired by the legendary healer Chiron, we harness the body's own regenerative power to tackle some of today's most urgent medical challenges.
From cosmetic skincare to orthopedic injuries and chronic diseases, we are committed to transforming advanced science into real-world healing—bridging the gap between innovation and impact.
Two cutting-edge autograft stem cell therapies in development. Backed by robust proof-of-concept data, our SIST technology demonstrates promising safer, scalable solutions for diseases like Orthopedic Disorders (cartilage regeneration) and Skin and Wound Healing (Burn injuries).
Our pipeline features two next-generation stem cell therapies, powered by our proprietary SIST platform. Backed by strong proof-of-concept data, these therapies offer safer, scalable alternatives for high-need indications:
Targeted cartilage regeneration for joint repair and mobility restoration
Accelerated healing for burn injuries and chronic wounds
With a focus on real-world applicability and clinical readiness, Chiron is building a pipeline designed to move swiftly from lab to patient.
Unlike traditional cosmetic ingredients that only act on the skin's surface, our stem cell-derived exosomes penetrate deeply into the skin, delivering powerful regenerative signals that awaken the body's own repair mechanisms.
Stem cell-derived exosomes rejuvenate skin at the cellular level, reducing wrinkles and enhancing hydration for sustained youthful radiance.
Exosomes accelerate healing of chronic wounds, diabetic ulcers, and post-surgical scars through powerful regenerative properties.
Discover our cutting-edge exosome-powered skincare solutions that go beyond traditional cosmetics
We have assembled a multidisciplinary team uniquely positioned to commercialize stem cells for cosmetic and therapeutic applications. By combining Tier‑1 expertise in stem cells, exosome technology, and formulation with proven industrial scale‑up capabilities, Chiron’s leadership ensures that our innovations are not only scientifically viable but also commercially scalable. We are committed to translating superior science into sustainable investor value.
Chief Executive Officer | Founder
Dr. Behzad Yeganeh is the visionary Founder and CEO of Chiron Therapeutics,.
Chief Scientific Officer | Regulatory Advisor | Co-Founder
Dr. Azadeh Yeganeh is a biomedical scientist and co-author of the SIST technology paper
Chief Product Officer | Co-Founder
Dr. Ali Hamraghani is a pharmaceutical R&D specialist with extensive experience in research, development
Dr. Behzad Yeganeh is the visionary Founder and CEO of Chiron Therapeutics, a seasoned biotech leader with over 15 years of experience translating complex biological discoveries into commercially viable assets. A two-time founder and serial entrepreneur, Dr. Yeganeh combines deep technical expertise in molecular biology with a proven track record of launching successful ventures anchored by proprietary intellectual property.
Dr. Azadeh Yeganeh is a biomedical scientist and co-author of the SIST technology paper with extensive research experience in stem cell biology, translational science, and regulatory strategy. Her work spans the development of adult stem cell platforms, including mesenchymal stromal cell (MSC)–derived exosomes, with a particular focus on their applications in longevity, tissue regeneration, and age-related disorders.
Dr. Ali Hamraghani is a Pharmaceutical Executive and GMP Specialist with over 15 years of experience in drug formulation, manufacturing scale-up, and quality assurance. As the Chief Product Officer at Chiron Therapeutics, he is responsible for transforming bench-side discoveries into industrial-grade commercial products. Dr. Hamraghani is uniquely qualified by a dual background in Clinical Pharmacy (PharmD) and Molecular Biology (M.Sc.), providing him with a holistic view of the product lifecycle from molecular conception to clinical application.
Guided by the leadership of Chair Dr. Azadeh Yeganeh, the Chiron Advisory Board acts as a cornerstone of our scientific and commercial governance. The board currently comprises distinguished scientists and industry veterans specializing in stem cell research, regenerative medicine, and regulatory compliance within the cosmetics sector. To accelerate our commercial roadmap, Chiron is actively expanding this body to include subject matter experts focused on capital formation and corporate strategy.
Strategic Advisor
Janice Taylor is a visionary tech entrepreneur, Harvard scholar, and three-time founder
Scientific Advisor
Dr. Post is a Professor at the University of Toronto and a Senior Scientist at the SickKids Research Institute in Toronto.
Scientific Advisor
Harvard and Johns Hopkins-trained Dr. Sherley is founder and CEO of Asymmetrex®
Janice Taylor serves as a Strategic Advisor to Chiron Therapeutics, bringing a powerhouse combination of entrepreneurial expertise and capital market success. As a three-time founder and Harvard scholar, Janice leverages her deep background in business strategy to guide Chiron’s vision at the intersection of science, technology, and market scalability.
Dr. Post is a Professor at the University of Toronto and a Senior Scientist at the SickKids Research Institute in Toronto. He leads a research group dedicated to lung development, injury, and repair. His team has pioneered the generation of human alveolar-like macrophages from stem cells as a potential cell therapy for lung diseases, including respiratory syncytial virus (RSV) and bacterial infections associated with cystic fibrosis, with the goal of mitigating disease severity and progression. With over 35 years of experience in lung injury, repair, and regenerative medicine, Dr. Post brings exceptional expertise to Chiron’s stem cell platform.
Harvard and Johns Hopkins-trained Dr. Sherley is founder and CEO of Asymmetrex®, which pioneered differential tissue stem cell counting for accurate dosage certification and manufacturing optimization. A recipient of NIH Director’s Pioneer Award, he serves on committees for the American Society for Testing and Materials International and the Advanced Regenerative Manufacturing Institute, bringing invaluable expertise to Chiron’s stem cell platform.
Dr. Behzad Yeganeh is the visionary Founder and CEO of Chiron Therapeutics, a seasoned biotech leader with over 15 years of experience translating complex biological discoveries into commercially viable assets. A two-time founder and serial entrepreneur, Dr. Yeganeh combines deep technical expertise in molecular biology with a proven track record of launching successful ventures anchored by proprietary intellectual property.
As the inventor of the revolutionary SIST technology, Dr. Yeganeh achieved a breakthrough high yield in generation of adult stem cell without genetic modification. This IP-licensed invention positions Chiron Therapeutics at the forefront of regenerative innovation, unlocking transformative therapeutic and cosmetic applications for adult stem cells.
Dr. Yeganeh’s leadership extends from bench to pre-clinical validation, including extensive experience in GMP manufacturing and regulatory strategy, notably with Health Canada. He has demonstrated a strong ability to secure non-dilutive funding and drive R&D strategies that bridge the gap between scientific innovation and market reality.
Dr. Azadeh Yeganeh is a biomedical scientist and co-author of the SIST technology paper with extensive research experience in stem cell biology, translational science, and regulatory strategy. Her work spans the development of adult stem cell platforms, including mesenchymal stromal cell (MSC)–derived exosomes, with a particular focus on their applications in longevity, tissue regeneration, and age-related disorders. Her background includes leading preclinical stem-cell programs, overseeing process and product development, and guiding early-stage therapeutics through complex regulatory pathways. Dr. Azadeh Yeganeh brings deep knowledge of clinical translation, regulatory planning, and risk-based product development, with hands-on experience navigating early-stage regulatory pathways and quality frameworks for advanced biological products. As Chief Scientific Officer and Regulatory Advisor at Chiron Therapeutics, she oversees all scientific and preclinical development efforts and provides strategic guidance on regulatory strategy, quality systems, and future clinical trial planning—positioning Chiron to efficiently and responsibly advance its platform from the laboratory to clinical and commercial applications.
Dr. Ali Hamraghani is a Pharmaceutical Executive and GMP Specialist with over 15 years of experience in drug formulation, manufacturing scale-up, and quality assurance. As the Chief Product Officer at Chiron Therapeutics, he is responsible for transforming bench-side discoveries into industrial-grade commercial products. Dr. Hamraghani is uniquely qualified by a dual background in Clinical Pharmacy (PharmD) and Molecular Biology (M.Sc.), providing him with a holistic view of the product lifecycle from molecular conception to clinical application.
Throughout his career, Dr. Hamraghani has successfully led the technology transfer of more than 18 pharmaceutical products to market. His expertise spans advanced drug formulation, impurity profiling, and managing production under rigorous global standards, including Novartis-licensed protocols. He specializes in establishing Good Manufacturing Practices (GMP) and validating computerized systems (Data Integrity) to ensure regulatory compliance.
Currently, Dr. Hamraghani is leading Chiron’s critical transition from R&D to pilot-scale manufacturing. He applies his skills in process validation and efficiency to support the company’s innovation in exosome-based skincare solutions, ensuring they meet the highest standards of safety and scalability.
Janice Taylor serves as a Strategic Advisor to Chiron Therapeutics, bringing a powerhouse combination of entrepreneurial expertise and capital market success. As a three-time founder and Harvard scholar, Janice leverages her deep background in business strategy to guide Chiron’s vision at the intersection of science, technology, and market scalability.
Her track record in fundraising is exceptional; she has personally raised over $15 million for her own ventures and has advised founders in securing more than $1 billion in funding. Janice applies this acute business acumen to Chiron, advising on growth strategy, investor relations, and the commercialization of transformative health technologies.
Beyond her role at Chiron, Janice is a visionary tech entrepreneur dedicated to redefining human potential. She is the creator of the “Emotional Fitness” methodology and CEO of AH-HA Healing, where she pioneers AI-driven wellness innovation. Janice’s leadership history includes high-level initiatives with the NFL, NHL, NBA, and MLS, as well as developing award-winning AI platforms that have influenced digital safety policy in Canada and the U.S. She has been recognized as one of the “Extraordinary Women in Tech” by the Canadian Consulate, appointed Honorary Captain of the Royal Canadian Navy, and featured on global stages including TEDx and Oprah Winfrey.